Drugs / P2Et
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04410510 | Sep 2020 → Jun 2021 | COVID-19 | Hospital Universitario San Ignacio | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05007444 Comparator | Mar 2022 → Jun 2023 | breast cancer | Hospital Universitario San Ignacio | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | P2Et | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04410510 ↗ |
| Known as | Caesalpinia spinosa extract | “P2Et (Caesalpinia spinosa extract)” NCT04410510 ↗1“P2Et (Caesalpinia spinosa extract)” NCT05007444 ↗ |
| Action | Inhibit | “P2Et was able to reduce the viral replication of murine and human coronaviruses in vitro, showing its dual antiviral and anti-inflammatory role, key in disease control.” PMID 36160152 ↗ Sep 2022 |
| Modality | Traditional medicine (herbal / TCM) | “traditional herbal medicine” NCT05007444 ↗ |